undamentalytics Newsletter
Sign in

Zhengye Biotechnology Holding Ltd revenue

Zhengye Biotechnology Holding Ltd's revenue was $16.2m in fiscal 2025, down 37.5% on the year before. Since fiscal 2022 ($38.8m) it has grown at a compound -25.2% a year.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2022Dec 20222023Dec 20232024Dec 20242025Dec 2025
Revenue39302616
Growth on the year before—−22.8%−13.4%−37.5%
Gross profit2217133
Gross margin56.8%55.5%49.0%20.5%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Pharmaceuticals: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Zhengye Biotechnology Holding Ltd $16.2m -37.5% —
Sol-gel Technologies Ltd. $19.4m 68.0% —
Jaguar Health, Inc. $27.8m 135.5% 76.5%
Verrica Pharmaceuticals Inc. $30.3m 106.2% 52.2%
Scilex Holding Co $31.6m -28.5% -12.0%
Sunshine Biopharma Inc. $35.3m -2.7% 34.5%

Compare with peers

Head to head: SLGL vs ZYBTJAGX vs ZYBTVRCA vs ZYBT

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Zhengye Biotechnology Holding Ltd's SEC filings (10-K and 10-Q). How we read and check them: methodology and data sources. Not investment advice. Back to Zhengye Biotechnology Holding Ltd.